Compare BioNano Genomics Inc (BNGO) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.76. The key difference: Roundhill Innov-100 0DTE Covered Call Strat ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | QDTE | |
|---|---|---|
Market Cap | $13.66M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $4.92 | $36.60 |
52-Week Low | $1.06 | $26.85 |
Enterprise Value | $16.26M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
QDTE trades at $29.80, up 0.51% on the day, with a bearish technical signal from moving averages and oscillators showing neutral momentum. The fund faces scrutiny over its high distribution yield, which is reportedly funded by return of capital, leading to net asset value erosion. Recent news highlights underperformance in bull markets and concerns about the sustainability of its weekly payout strategy.
The outlook is cautious due to structural risks in the covered call strategy, with potential for continued NAV decline outweighing the attractive yield. Investors should weigh the income benefits against the risk of capital depletion, as analyst sentiment has turned negative with recent downgrades emphasizing the fund's vulnerability to market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
